CA3112200A1 - Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof - Google Patents

Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof Download PDF

Info

Publication number
CA3112200A1
CA3112200A1 CA3112200A CA3112200A CA3112200A1 CA 3112200 A1 CA3112200 A1 CA 3112200A1 CA 3112200 A CA3112200 A CA 3112200A CA 3112200 A CA3112200 A CA 3112200A CA 3112200 A1 CA3112200 A1 CA 3112200A1
Authority
CA
Canada
Prior art keywords
crystalline form
trifluoromethoxy
crystalline
piperazine
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112200A
Other languages
English (en)
French (fr)
Inventor
Lianfeng Huang
Nancy TSOU
Nicole Suzanne White
Jun Xu
Qun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Lundbeck La Jolla Research Center Inc
Original Assignee
Celgene Corp
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Abide Therapeutics Inc filed Critical Celgene Corp
Publication of CA3112200A1 publication Critical patent/CA3112200A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3112200A 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof Pending CA3112200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
US62/731,014 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3112200A1 true CA3112200A1 (en) 2020-03-19

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112200A Pending CA3112200A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
KR20210057789A (ko) 2021-05-21
US11053199B2 (en) 2021-07-06
MA53607A (fr) 2021-12-22
EP4434583A2 (en) 2024-09-25
JP2022500441A (ja) 2022-01-04
HUE068147T2 (hu) 2024-12-28
KR102844245B1 (ko) 2025-08-11
ES2993173T3 (en) 2024-12-23
WO2020056105A9 (en) 2020-07-09
MX2021002923A (es) 2021-09-08
FI4434583T3 (fi) 2026-05-15
HRP20260757T1 (hr) 2026-08-14
EP4434583B1 (en) 2026-04-01
PL3849970T3 (pl) 2025-01-07
AU2019337623A1 (en) 2021-05-13
US20210363105A1 (en) 2021-11-25
RS68181B1 (sr) 2026-06-30
LT3849970T (lt) 2024-10-10
US20260062384A1 (en) 2026-03-05
US11680046B2 (en) 2023-06-20
PL4434583T3 (pl) 2026-07-20
DK4434583T5 (da) 2026-07-06
EP4434583A3 (en) 2024-11-20
SG11202102143RA (en) 2021-04-29
MY208901A (en) 2025-06-09
EP3849970A1 (en) 2021-07-21
AU2019337623B2 (en) 2024-12-05
IL281276A (en) 2021-04-29
SMT202400369T1 (it) 2024-11-15
EP4768081A2 (en) 2026-07-01
EA202190511A1 (ru) 2021-07-05
EP3849970B1 (en) 2024-07-03
SMT202600252T1 (it) 2026-07-16
PT3849970T (pt) 2024-09-25
SI3849970T1 (sl) 2024-11-29
IL281276B2 (en) 2025-01-01
IL281276B1 (en) 2024-09-01
CN113227069B (zh) 2024-11-05
MY210363A (en) 2025-09-13
CL2021000596A1 (es) 2021-07-30
LT4434583T (lt) 2026-06-25
DK4434583T3 (da) 2026-06-15
PT4434583T (pt) 2026-06-11
US12410133B2 (en) 2025-09-09
US20200095201A1 (en) 2020-03-26
WO2020056105A1 (en) 2020-03-19
MA53607B1 (fr) 2025-05-30
RS65967B1 (sr) 2024-10-31
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
CN118530218A (zh) 2024-08-23
FI3849970T3 (fi) 2024-09-20
CO2021003295A2 (es) 2021-07-30
ES3072981T3 (en) 2026-07-07
US20230382861A1 (en) 2023-11-30
MA71839B1 (fr) 2026-05-26
CN113227069A (zh) 2021-08-06
BR112021004340A2 (pt) 2021-05-25
CN118561814A (zh) 2024-08-30
DK3849970T3 (da) 2024-09-30

Similar Documents

Publication Publication Date Title
EP3102575A1 (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20260062384A1 (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
US11866417B2 (en) Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10919873B2 (en) Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US20210107888A1 (en) Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
HK40111401A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
HK40053390A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
HK40053390B (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
EA043074B1 (ru) Кристаллический (r)-5-карбамоилпиридин-3-ил-2-метил-4-(3-(трифторметокси)бензил)пиперазин-1-карбоксилат, его композиции и способы применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240731

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250602

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250602

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250729

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250919

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251002

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251002

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251002

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED

Effective date: 20251107

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260630

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260710

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260710

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260729